MedPath

Study on the Improvement of Microcirculation in Patients With Sepsis by Vitamin B6, Vitamin B12 and Vitamin C

Not Applicable
Recruiting
Conditions
Septic Shock
Interventions
Drug: vitamin B6+ Vitamin B12 +vitamin C
Drug: vitamin B6+ Vitamin B12
Drug: vitamin C
Drug: 0.9%Nacl
Registration Number
NCT06749756
Lead Sponsor
Fan Zeng
Brief Summary

Sepsis is a kind of disease with high morbidity and mortality in ICU. At present, there is no specific treatment, and its pathogenesis is mainly excessive oxidative stress. Anti-inflammatory, antioxidant and immune-regulating drugs may produce better therapeutic effects, while vitamin B6, vitamin B12 and vitamin C have anti-inflammatory, antioxidant and immune-regulating effects. The purpose of this study was to investigate whether vitamin B6, vitamin B12 combined with vitamin C can improve the microcirculation and organ dysfunction in patients with sepsis, and improve the survival rate of patients with sepsis. The study included 296 patients who met the inclusion criteria. After randomization, the experimental group was given intravenous vitamin B6 300mg qd in addition to the basic treatment of sepsis Vitamin B12 0.5mg q6h, vitamin C 50mg/kg q6h for 4 days. Control group 1 was given vitamin B6 300mg qd and vitamin B12 0.5mg q6h intravenously for 4 days. Control group 2 was injected with vitamin C 50mg/kg q6h intravenously for 4 days. Control group 3: The same dose of placebo (0.9% sodium chloride solution) was administered for 4 days. After medication, sublingual microcirculation image and radial artery resistance index of snus pit were detected and recorded according to the time required by the study protocol. The duration of use of pressor drugs, ventilator days, ICU stay, 28-day mortality, capillary refill time, changes in SOFA score and APACHEII score on day 3 and day 7 compared with baseline values at randomization, daily veno-arterial carbon dioxide differential pressure (GAP) and central venous oxygen saturation were recorded. After the end of the experiment, statistical analysis of the data was carried out to further explore the test results

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
296
Inclusion Criteria
  1. Age ≥18 and < 85 years old

  2. Admitted to ICU

  3. Diagnosis of patients with SEPSIS 3.0 (diagnostic criteria) 4, SOFA score is 2-13 points

  4. Obtain the informed consent of the subject or his family

Read More
Exclusion Criteria
  1. Patients have absolute contraindications such as vitamin allergy
  2. Patients with a history of gout
  3. Death is expected within 24 hours
  4. Pregnant women
  5. Use hydroprednisone or other equivalent dose hormones > 200mg/d within 24 hours
  6. Without the informed consent of the patient or his/her representative
  7. Patients with a history of scleroderma
  8. Patients with a history of vasculitis
  9. Patients with oral mucosal diseases
  10. Patients with severe difficulty in opening their mouth and unable to detect sublingual microcirculation
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental groupvitamin B6+ Vitamin B12 +vitamin CIn addition to the basic treatment of sepsis, intravenous injection of vitamin B6 300mg qd Vitamin B12 0.5mg q6h, vitamin C 50mg/kg q6h for 4 days.
Control group 1vitamin B6+ Vitamin B12In addition to the basic treatment of sepsis, vitamin B6 300mg qd and vitamin B12 0.5mg q6h were given intravenously for 4 days.
Control group 2vitamin COn the basis of the basic treatment of sepsis, intravenous vitamin C 50mg/kg q6h was given for 4 days.
Control group 30.9%NaclThe same dose of placebo (0.9% sodium chloride solution) was administered on top of the sepsis base treatment for 4 days.
Primary Outcome Measures
NameTimeMethod
Improvement of microcirculationAt 0 hour, 6hours, 24hours, 48hours, 4 days, and 7 days after initiation of administration.

The radial artery resistance index of snus pit was measured after the start of administration.

Secondary Outcome Measures
NameTimeMethod
28-day mortality28 days

28-day mortality

Capillary refill time4 days

Capillary refill time during trial medication

Changes in SOFA score7 days

Changes in SOFA scores on day 3 and day 7 compared with baseline values at randomization.The SOFA Score (Sequential Organ Failure Assessment Score) is a scoring system used to assess the severity of organ dysfunction in critically ill patients. It consists of six systems: respiratory, blood, liver, cardiovascular, nervous and kidney, with each system scored according to the degree of dysfunction on a scale of 0 (normal) to 4 (severe impairment or failure). The score of SOFA is closely related to the mortality and prognosis of patients. The higher the score, the higher the mortality.

Changes in APACHEII score7 days

Changes in APACHEII scores on day 3 and day 7 compared with baseline values at randomization.The Apache II score, also known as the Acute Physiological and Chronic Health Assessment (APACHE II), is a scoring system used to assess the severity of a critically ill patient's condition and predict prognosis. The theoretical maximum value is 71 points, and the higher the score, the more severe the disease, the worse the prognosis and the higher the fatality rate.

Daily change of veno-arterial carbon dioxide differential pressure (GAP)4 days

Daily change of veno-arterial carbon dioxide differential pressure (GAP)

Daily change of central venous oxygen saturation (Scv02)4 days

Daily change of central venous oxygen saturation (Scv02)

Number of days on ventilator28 days

The number of days the patient was ventilator-ventilated within 28 days

The duration of the patient's use of pressor drugs4 days

Duration of pressor drug use during the patient's trial medication

ICU stay28 days

Patient's 28-day ICU stay

Trial Locations

Locations (1)

Sichuan Provincial People's Hospital

🇨🇳

Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath